Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Safety was equally impressive. ENV-294 was well tolerated
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
